126 related articles for article (PubMed ID: 38224547)
1. Comment on: Treatment efficacy and safety of adalimumab versus tocilizumab in patients with active and severe Takayasu arteritis.
Misra DP
Rheumatology (Oxford); 2024 May; 63(5):e156-e157. PubMed ID: 38224547
[No Abstract] [Full Text] [Related]
2. Treatment efficacy and safety of adalimumab versus tocilizumab in patients with active and severe Takayasu arteritis: an open-label study.
Wang J; Kong X; Ma L; Ding Z; Chen H; Chen R; Jin X; Chen C; Lin J; Jiang L
Rheumatology (Oxford); 2024 May; 63(5):1359-1367. PubMed ID: 37540159
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Biological-Targeted Treatments in Takayasu Arteritis: Multicenter, Retrospective Study of 49 Patients.
Mekinian A; Comarmond C; Resche-Rigon M; Mirault T; Kahn JE; Lambert M; Sibilia J; Néel A; Cohen P; Hie M; Berthier S; Marie I; Lavigne C; Anne Vandenhende M; Muller G; Amoura Z; Devilliers H; Abad S; Hamidou M; Guillevin L; Dhote R; Godeau B; Messas E; Cacoub P; Fain O; Saadoun D;
Circulation; 2015 Nov; 132(18):1693-700. PubMed ID: 26354797
[TBL] [Abstract][Full Text] [Related]
4. Treatment of childhood-onset Takayasu arteritis: switching between anti-TNF and anti-IL-6 agents.
Sener S; Basaran O; Kaya Akca U; Atalay E; Kasap Cuceoglu M; Balik Z; Aliyev E; Bayindir Y; Batu ED; Hazirolan T; Bilginer Y; Ozen S
Rheumatology (Oxford); 2022 Nov; 61(12):4885-4891. PubMed ID: 35262635
[TBL] [Abstract][Full Text] [Related]
5. Utility and safety of tocilizumab in Takayasu arteritis with severe heart failure and muscle wasting.
Yano T; Osanami A; Shimizu M; Katano S; Nagano N; Kouzu H; Koyama M; Muranaka A; Harada R; Doi H; Kawaharada N; Miura T
ESC Heart Fail; 2019 Aug; 6(4):894-897. PubMed ID: 31297975
[TBL] [Abstract][Full Text] [Related]
6. Sustained inflammation of the aortic wall despite tocilizumab treatment in two cases of Takayasu arteritis.
Xenitidis T; Horger M; Zeh G; Kanz L; Henes JC
Rheumatology (Oxford); 2013 Sep; 52(9):1729-31. PubMed ID: 23463808
[No Abstract] [Full Text] [Related]
7. Efficacy of tocilizumab in Takayasu arteritis: Multicenter retrospective study of 46 patients.
Mekinian A; Resche-Rigon M; Comarmond C; Soriano A; Constans J; Alric L; Jego P; Busato F; Cabon M; Dhote R; Estibaliz L; Koné-Paut I; Landron C; Lavigne C; Lioger B; Michaud M; Ruivard M; Sacre K; Gottenberg JE; Gaches F; Goulenok T; Salvarani C; Cacoub P; Fain O; Saadoun D;
J Autoimmun; 2018 Jul; 91():55-60. PubMed ID: 29678346
[TBL] [Abstract][Full Text] [Related]
8. Takayasu Arteritis: It Is Time to Work Together.
Beckman JA
Circulation; 2015 Nov; 132(18):1685-6. PubMed ID: 26354798
[No Abstract] [Full Text] [Related]
9. Dramatic Response to Tocilizumab Before Emergency Surgery in Severe Active Takayasu Disease.
Risse J; Mandry D; Settembre N; Vigouroux C; Claudin M; Tsintzila G; Huttin O; Malikov S; Zuily S; Wahl D
Circ Cardiovasc Imaging; 2016 Jul; 9(7):. PubMed ID: 27406844
[No Abstract] [Full Text] [Related]
10. Rapid control of disease activity by tocilizumab in 10 'difficult-to-treat' cases of Takayasu arteritis.
Goel R; Danda D; Kumar S; Joseph G
Int J Rheum Dis; 2013 Dec; 16(6):754-61. PubMed ID: 24382284
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.
Burmester GR; Lin Y; Patel R; van Adelsberg J; Mangan EK; Graham NM; van Hoogstraten H; Bauer D; Ignacio Vargas J; Lee EB
Ann Rheum Dis; 2017 May; 76(5):840-847. PubMed ID: 27856432
[TBL] [Abstract][Full Text] [Related]
12. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
McInnes IB; Behrens F; Mease PJ; Kavanaugh A; Ritchlin C; Nash P; Masmitja JG; Goupille P; Korotaeva T; Gottlieb AB; Martin R; Ding K; Pellet P; Mpofu S; Pricop L;
Lancet; 2020 May; 395(10235):1496-1505. PubMed ID: 32386593
[TBL] [Abstract][Full Text] [Related]
13. [Tocilizumab for refractory Takayasu arteritis with aortic aneurysm].
Frikha F; Garbaa S; Bouattour Y; Snoussi M; Loukil H; Ben Salah R; Bahloul Z
J Med Vasc; 2019 May; 44(3):237-239. PubMed ID: 31029281
[TBL] [Abstract][Full Text] [Related]
14. Tocilizumab treatment effectively improves coronary artery involvement in patients with Takayasu arteritis.
Pan L; Du J; Liu J; Liao H; Liu X; Guo X; Liang J; Han H; Yang L; Zhou Y
Clin Rheumatol; 2020 Aug; 39(8):2369-2378. PubMed ID: 32144625
[TBL] [Abstract][Full Text] [Related]
15. Tocilizumab treatment in childhood Takayasu arteritis: Case series of four patients and systematic review of the literature.
Batu ED; Sönmez HE; Hazırolan T; Özaltın F; Bilginer Y; Özen S
Semin Arthritis Rheum; 2017 Feb; 46(4):529-535. PubMed ID: 27515155
[TBL] [Abstract][Full Text] [Related]
16. Treatment of refractory Takayasu arteritis with tocilizumab: 7 Italian patients from a single referral center.
Tombetti E; Franchini S; Papa M; Sabbadini MG; Baldissera E
J Rheumatol; 2013 Dec; 40(12):2047-51. PubMed ID: 24187104
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of anti-interleukin 6 receptor monoclonal antibody (tocilizumab) in Colombian patients with Takayasu arteritis.
Cañas CA; Cañas F; Izquierdo JH; Echeverri AF; Mejía M; Bonilla-Abadía F; Tobón GJ
J Clin Rheumatol; 2014 Apr; 20(3):125-9. PubMed ID: 24662551
[TBL] [Abstract][Full Text] [Related]
18. Generalized estimating equation model to compare drug effects on synovitis of the dominant wrist in severe rheumatoid arthritis between tocilizumab versus adalimumab versus abatacept using high-resolution ultrasound.
Chen YC; Chiu WC; Su FM; Chen JF
Int J Rheum Dis; 2018 Sep; 21(9):1695-1700. PubMed ID: 29024421
[TBL] [Abstract][Full Text] [Related]
19. Infliximab in Takayasu arteritis: a safe alternative?
Karageorgaki ZT; Mavragani CP; Papathanasiou MA; Skopouli FN
Clin Rheumatol; 2007 Jun; 26(6):984-7. PubMed ID: 16633710
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension.
Burmester GR; Strand V; Rubbert-Roth A; Amital H; Raskina T; Gómez-Centeno A; Pena-Rossi C; Gervitz L; Thangavelu K; St John G; Boklage S; Genovese MC
RMD Open; 2019; 5(2):e001017. PubMed ID: 31673415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
